Erianin is primarily studied for its potential anticancer properties. It has shown inhibitory effects on the growth of various cancer cell lines by inducing apoptosis and blocking cell cycle progression. Research indicates it may suppress tumor angiogenesis, which is the formation of new blood vessels that feed tumors, thereby limiting cancer spread. It also exhibits anti-inflammatory and antioxidant activities, making it a candidate for further research in treating chronic inflammatory conditions and oxidative stress-related diseases. Some studies explore its use in combination with other anticancer agents to enhance therapeutic efficacy. Due to its natural origin and bioactivity, erianin is being investigated as a lead compound in drug development, particularly in oncology and immunomodulation.